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Abstract
IMPORTANCE—Interstitial lung abnormalities have been associated with decreased six-minute 
walk distance, diffusion capacity for carbon monoxide and total lung capacity; however to our 
knowledge, an association with mortality has not been previously investigated.
OBJECTIVE—To investigate whether interstitial lung abnormalities are associated with 
increased mortality.
DESIGN, SETTING, POPULATION—Prospective cohort studies of 2633 participants from the 
Framingham Heart Study (FHS) (CT scans obtained 9/08–3/11), 5320 from the Age Gene/
Environment Susceptibility (AGES)-Reykjavik (recruited 1/02–2/06), 2068 from COPDGene 
(recruited 11/07–4/10), and 1670 from the Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate End-points (ECLIPSE) (between 12/05–12/06).
EXPOSURES—Interstitial lung abnormality status as determined by chest CT evaluation.
MAIN OUTCOMES AND MEASURES—All cause mortality over approximately 3 to 9 year 
median follow up time. Cause-of-death information was also examined in the AGES-Reykjavik 
cohort.
RESULTS—Interstitial lung abnormalities were present in 177 (7%) of the participants from 
FHS, 378 (7%) from AGES-Reykjavik, 156 (8%) from COPDGene, and in 157 (9%) from 
ECLIPSE. Over median follow-up times of ~3–9 years there were more deaths (and a greater 
absolute rate of mortality) among those with interstitial lung abnormalities compared to those 
without interstitial lung abnormalities in each cohort; 7% compared to 1% in FHS (6% difference, 
95% confidence interval [CI] 2%, 10%), 56% compared to 33% in AGES-Reykjavik (23% 
difference, 95% CI 18%, 28%), 16% compared to 11% in COPDGene (5% difference, 95% CI 
−1%, 11%) and 11% compared to 5% in ECLIPSE (6% difference, 95% CI 1%, 11%). After 
adjustment for covariates, interstitial lung abnormalities were associated with an increase in the 
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risk of death in the FHS (HR=2.7, 95% CI, 1.1–65, P=0.030), AGES-Reykjavik (HR 1.3, 95% CI 
1.2–1.4, P<0.001), COPDGene (HR=1.8, 95% CI, 1.1, 2.8, P=0.014), and ECLIPSE (HR=1.4, 
95% CI, 1.1–2, P=0.022) cohorts. In the AGES-Reykjavik cohort the higher rate of mortality could 
be explained by a higher rate of death due to respiratory disease, specifically pulmonary fibrosis.
CONCLUSIONS AND RELEVANCE—In four separate research cohorts, interstitial lung 
abnormalities were associated with a higher risk of all-cause mortality. The clinical implications of 
this association require further investigation.
Keywords
Idiopathic pulmonary fibrosis; interstitial lung disease; interstitial lung abnormalities (ILA); 
undiagnosed; subclinical
Interstitial lung abnormalities are defined as specific patterns of increased lung density noted 
on chest computed tomography (CT) scans identified in participants with no prior history of 
interstitial lung disease. In studies of adults, interstitial lung abnormalities are present in ~2–
10% of research participants,1–7 and 7% of a general population sample,6 and are associated 
with reductions in lung capacity,1,2,6 exercise capacity,8 gas exchange,5,6 and genetic 
abnormalities6,9 common to patients with familial interstitial pneumonia and idiopathic 
pulmonary fibrosis (IPF).10 These data suggest that interstitial lung abnormalities may, in 
some cases, represent an early and/or mild form of pulmonary fibrosis.
While radiologic abnormalities, worsening pulmonary function and decreased exercise 
tolerance are important diagnostic features of IPF,11 the most common and severe form of 
pulmonary fibrosis,12 IPF is associated with a high mortality rate.13–14 Although the survival 
rate of people with IPF appears to have increased slightly in recent years,14 the previously 
published median survival after the time of diagnosis is 3–5 years,13–14 which is worse than 
that of most malignancies.15 Given the other correlations between IPF and interstitial lung 
abnormalities, we hypothesized that with the presence of interstitial lung abnormalities 
would be associated with an increased rate of mortality.
METHODS
Study Design and Mortality Ascertainment
Protocols for participant enrollment and phenotyping in the Framingham Heart Study (FHS), 
the Age Gene/Environment Susceptibility (AGES)-Reykjavik study, the Genetic 
Epidemiology of COPD Study (COPDGene), and the Evaluation of COPD Longitudinally to 
Identify Predictive Surrogate End-points (ECLIPSE) study have been described 
previously.2,6,16,17 In all cohorts race was self-reported, based on fixed categories. Analyses 
were adjusted for race, given the known influence of race on mortality in other pulmonary 
diseases. In all cohorts, mortality refers to all-cause mortality unless otherwise indicated. 
Informed consent was obtained from all participants. The institutional review boards of the 
Brigham and Women’s Hospital and individual participating centers approved this study.
The FHS is a longitudinal study originally designed to identify risk factors for 
cardiovascular disease in the general population18. The AGES-Reykjavik study is a 
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longitudinal birth cohort from the Reykjavik Study (established in 1967) that now includes 
men and women born in Reykjavik between 1907–1935 who are followed by the Icelandic 
Heart Association. COPDGene is a multicenter longitudinal study designed to identify the 
epidemiologic and genetic risk factors for COPD. Participants with known active lung 
diseases other than asthma, emphysema, or COPD were excluded.19 For this analysis 
COPDGene refers to the first 2508 participants.2 ECLIPSE is a multicenter and 
multinational 3-year observational study of 2164 COPD patients (Global Initiative for 
Chronic Obstructive Lung Disease [GOLD] stages 2–4)20 and 582 controls aged 40–75.21 
Participants with known respiratory disorders other than COPD were excluded.21 For these 
analyses, only the 2,164 COPD participants from ECLIPSE were included because 
longitudinal mortality data from control participants was not collected (see eMethods for 
further details on cohort study design).
Chest CT Analysis
The methods for chest CT characterization for interstitial lung abnormalities in the FHS and 
COPDGene cohorts have been reported previously2,6 and were used to characterize 
interstitial lung abnormalities in AGES-Reykjavik and ECLIPSE (see eMethods). In all 
cohorts, the chest CT scans were evaluated by up to three readers (two chest radiologists and 
one pulmonologist) using a sequential reading method, as previously described.22 Interstitial 
lung abnormalities were defined as particular patterns of increased lung density that are not 
limited to the posterior regions of the lung, including ground-glass or reticular 
abnormalities, diffuse centrilobular nodularity, nonemphysematous cysts, honeycombing or 
traction bronchiectasis, affecting more than 5% of any lung zone (see eFigure 1). Chest CT 
images with focal or unilateral ground-glass attenuation, focal or unilateral reticulation or 
patchy ground glass abnormalities (<5%) were considered indeterminate (see eFigure 2). To 
explore the association between undiagnosed pulmonary fibrosis and mortality, an additional 
subset of interstitial lung abnormalities with pulmonary parenchymal architectural distortion 
diagnostic of fibrotic lung disease (definite fibrosis, see Figure 1A–D) was created.6 
Quantitative total lung volume and emphysema (percentage below −950 Hounsfield units) 
where reported were measured with Airway Inspector (www.airwayinspector.org) as 
previously described.23 Coronary artery calcium (CAC) scores were calculated using the 
traditional Agatston scoring method.24
Statistical Analyses
In all cohorts except the FHS, association analyses between pairs of variables were 
conducted with Fisher’s exact tests (for categorical variables) and two-tailed t-tests (for 
continuous variables). In the FHS, all analyses accounted for familial relationships using 
generalized estimating equations as previously described.25 To evaluate the association 
between interstitial lung abnormalities and mortality logistic regression was used (for 
absolute mortality) and Cox proportional hazards models (for time-to-mortality) with robust 
standard errors to account for familial correlation in FHS. In Cox models, all variables were 
assessed, and none violated the proportional hazards assumption. Multivariable models 
included adjustments for age, race, gender, body-mass index (BMI), pack-years of smoking, 
smoking status (current vs. former), Global initiative for chronic Obstructive Lung Disease 
(GOLD) stage (where available). Additional covariates used included measures of coronary 
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artery disease (CAD) (self-report of [or adjudicated in the FHS] CAD as well as CAC 
scores) and history of self-reported non-dermatologic malignancy. In the COPD cohorts, 
additional analyses were done using the Body-mass index, air flow Obstruction, Dyspnea 
and Exercise (BODE) index26, as an alternative measure of COPD severity. All p-values 
reported are two-sided and a level of 0.05 was considered statistically significant. SAS 
version 9.4 (SAS Institute, Cary, NC) was used for analyses in the AGES-Reykjavik, 
COPDGene and ECLIPSE cohorts and R version 3.1.3 was used for analyses in the FHS.
RESULTS
In the FHS, of the 2764 participants from the FHS-MDCT2 study between September 2008 
and March 2011, 2633 (95%) had chest CT and mortality reports as of December 2013 
(median follow-up time of 4.0 years) and were included. In AGES-Reykjavik, of the 5764 
participants recruited between January 2002 and February 2006, 5320 (92%) had chest CT 
and mortality data as of December 2013 (median follow up time of 8.9 years) and were 
included. Additionally, cause-of-death data obtained from death certificates (ICD9 and 
ICD10 codes, see eMethods), was collected in December 2009 (median follow up time of 
5.3 years). In COPDGene, of the first 2508 participants recruited between November 2007 
and April 2010, 2068 (82%) had chest CT and mortality information as of October 2015 
(median follow-up time of 6.5 years) and were included. In ECLIPSE, of the 2,164 
participants recruited between December 2005 and December 2006, 1670 (77%) had both 
chest CT and mortality information (median follow-up time of 2.9 years) and were included.
Interstitial Lung Abnormality Prevalence
The prevalence of participants with interstitial lung abnormalities, indeterminate interstitial 
lung abnormality status, and without interstitial lung abnormalities in the FHS6 and 
COPDGene cohorts2 have been previously reported and similar percentages were noted in 
these subsets (in the FHS, interstitial lung abnormalities were present in 177 [7%], 1086 
[41%] had indeterminate status and 1370 [52%] did not have interstitial abnormalities; in 
COPDGene, 156 [8%] had interstitial lung abnormalities, 739 36%] were indeterminate and 
1173 57%] did not have interstitial lung abnormalities, see Table 1 and Figure 2). In the 
AGES-Reykjavik cohort, interstitial lung abnormalities were present in 378 (7%), 1726 
(32%) had indeterminate status and 3216 (61%) had no interstitial lung abnormalities (see 
Table 1 and Figure 2). In ECLIPSE, interstitial lung abnormalities were present in 157 (9%), 
985 (59%) had indeterminate status, and 528 (32%) had no interstitial lung abnormalities 
(see Table 1 and Figure 2). Additional results about reading methodology are included in the 
eResults.
Baseline Characteristics and Interstitial Lung Abnormalities
The baseline characteristics of the participants from all four cohorts, stratified by the 
presence or absence of interstitial lung abnormalities, are presented in Table 1. Baseline 
characteristics of AGES-Reykjavik and ECLIPSE including those indeterminate for 
interstitial lung abnormalities are included in eTable 1 and 2. Across all cohorts, interstitial 
lung abnormalities were associated with older age compared to the absence of interstitial 
lung abnormalities. As previously noted in COPDGene2 compared to, among participants in 
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ECLIPSE23 interstitial lung abnormalities were associated with less severe airway 
obstruction as demonstrated by a higher forced expiratory volume in one second (FEV1) and 
FEV1/forced vital capacity (FVC) ratio, compared to absence of interstitial lung 
abnormalities. In contrast, in the FHS, interstitial lung abnormalities were associated with a 
higher prevalence of COPD and a lower FEV1/FVC ratio.
Mortality and Interstitial Lung Abnormalities
The absolute mortality rates were significantly higher in participants with interstitial lung 
abnormalities compared to those without interstitial lung abnormalities in all cohorts (see 
Table 2). In the FHS 7% (12 deaths) of participants with interstitial lung abnormalities died 
over 4 years compared to 1% (12 deaths) of those without interstitial abnormalities; in the 
AGES-Reykjavik 56% (210 deaths) of participants with interstitial lung abnormalities and 
33% (1065 deaths) of participants without interstitial lung abnormalities died over 8.9 years. 
In smokers with and without COPD from COPDGene, 16% (25 deaths) of participants with 
interstitial lung abnormalities died, while 11% (133 deaths) of participants without 
interstitial lung abnormalities died over 6.5 years. In smokers with COPD from ECLIPSE 
11% (18 deaths) of participants with interstitial lung abnormalities died over 2.9 years, while 
5% (27 deaths) of participants without interstitial lung abnormalities died. These findings 
resulted in a 6% difference (95% confidence interval [CI] 2%, 10%) in the FHS, a 23% 
difference (95% CI 18%, 28%) in AGES-Reykjavik, a 5% difference (95% CI −1%, 11%) in 
COPDGene, and a 6% difference (95% CI 1%, 11%) in ECLIPSE in the absolute mortality 
rates associated with interstitial lung abnormalities. The mortality rates in those with 
indeterminate status were 2% (24 deaths) in FHS, 43% (750 deaths) in AGES-Reykjavik, 
13% (99 deaths) in COPDGene and 12% (120 deaths) in ECLIPSE.
When compared to those without interstitial lung abnormalities in multivariable Cox 
proportional hazards models adjusting for age, sex, race, body mass index, pack-years of 
smoking, current smoking status and GOLD stage (where available), interstitial lung 
abnormalities were associated with a higher risk of death in the FHS (hazard ratio [HR]=2.7, 
95% confidence interval [CI], 1.1–6.5, P=0.030), AGES-Reykjavik (HR=1.3, 95% CI 1.2–
1.4, P<.001), COPDGene (HR=1.8, 95% CI 1.1, 2.8, P=0.014) and ECLIPSE (HR=1.4, 95% 
CI, 1.1–2.0, P=0.022) (see Figure 3). Similar results were seen, with higher odds of death, 
when using multivariable logistic regression (see eTable 3). For further analyses with respect 
to definite fibrosis and those indeterminate for interstitial lung abnormalities see the 
eResults, eTables 5 and 6 and eFigure 3.
Mortality, Interstitial Lung Abnormalities and Never-Smokers
To determine if unmeasured differences in smoking behavior among smokers could explain 
the associations between interstitial lung abnormalities and mortality, associations between 
interstitial lung abnormalities and mortality in never-smokers from both the FHS and AGES-
Reykjavik cohorts were analyzed. In the FHS, 6% of never smokers with interstitial lung 
abnormalities died, compared to 0.3% of never smokers without interstitial abnormalities, a 
difference of 5.7% (95% CI 1%, 12%), (HR 19.9, 95% CI 5.1–78.1, P<0.001). In AGES-
Reykjavik 52% of never smokers with interstitial lung abnormalities died compared to 31% 
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of those without interstitial lung abnormalities, a difference of 21%, (95% CI 11%, 31%), 
(HR=1.3, 95% CI 1.1–1.4, P=0.002).
Mortality, Interstitial Lung Abnormalities, COPD, CAD, and Cancer
To determine if the presence of other chronic diseases could explain the associations 
between interstitial lung abnormalities and mortality, analyses were performed in each 
cohort additionally adjusting for the percentage of emphysematous lung, measures of CAD 
or reports of malignancy (where available). The association between interstitial lung 
abnormalities and mortality remained statistically significant after additional adjustments for 
disease specific measures (see Table 2), except in the FHS and COPDGene, in which 
additional adjustment for adjudicated CAD and CAC scores resulted in no association (see 
Table 2). Similar associations between interstitial lung abnormalities and mortality were 
seen in COPDGene and ECLIPSE when adjusting for BODE Index (see eResults). 
Additionally, the absolute mortality rates of each GOLD stage were consistently greater in 
participants with interstitial lung abnormalities compared to those without interstitial lung 
abnormalities (see eFigure 4).
Mortality, Interstitial Lung Abnormalities and Cause-of-Death
To determine the causes-of-death among those with interstitial lung abnormalities, data from 
the AGES-Reykjavik cohort was assessed where causes-of-death were available on death 
certificates from an interim follow up date (December 31, 2009, median follow-up of 5.4 
years). Participants with interstitial lung abnormalities in the AGES-Reykjavik cohort were 
more likely to die from a respiratory cause (13%) compared to those without interstitial lung 
abnormalities (4%) or those with indeterminate status (6%, see Figure 2). After adjusting for 
covariates (age, sex, race, body mass index, pack-years of smoking, current smoking status), 
those with interstitial lung abnormalities had higher odds of death from a respiratory cause 
(Odds Ratio 2.4, 95% CI 1.7–3.4, P<0.001) compared to those without interstitial lung 
abnormalities. Results were similar when comparing those with interstitial lung 
abnormalities to those indeterminate for interstitial lung abnormalities (see eResults). After 
adjusting for covariates there was no association between interstitial lung disease status and 
death due to cardiovascular disease, cancer, or other deaths. Among participants who died 
from a respiratory cause, interstitial lung abnormalities were associated with an increased 
rate of dying from pulmonary fibrosis (47%], 7 of the 15 respiratory deaths among those 
with interstitial lung abnormalities were due to pulmonary fibrosis, see Figure 2). Of the 
eight deaths due to pulmonary fibrosis, 5 participants had evidence of definite fibrosis on 
chest CT, 2 had interstitial lung abnormalities without definite fibrosis, and 1 participant was 
indeterminate for interstitial lung abnormality status. Only one of these participants had 
previously diagnosed pulmonary fibrosis at the time of the CT scan.
Discussion
In this study, interstitial lung abnormalities, a set of imaging abnormalities noted among 
~7% adults,6 were associated with a higher rate of all-cause mortality. The associations 
between interstitial lung abnormalities and mortality were not attenuated after adjustment by 
smoking, cancer, or COPD or CAD. Among an older population from Iceland, the higher 
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rate of mortality in those with interstitial lung abnormalities was associated with a higher 
rate of death from respiratory failure and pulmonary fibrosis. These findings, in conjunction 
with those previously published,2,6,8 demonstrate that despite often being undiagnosed and 
asymptomatic,2,6 interstitial lung abnormalities may be associated with lower survival rates 
among older persons.
This study builds on prior studies7, demonstrating that interstitial lung abnormalities were 
associated with older age, smoking, and a restrictive lung deficit. The findings in ECLIPSE 
are similar to those previously reported in COPDGene2 which demonstrate that among 
smokers with COPD, interstitial lung abnormalities were identified in those with more 
preserved FEV1/FVC ratios. Although COPD was associated with interstitial lung 
abnormalities in the FHS, this association may be related to older age and history of 
smoking that are common in both COPD and interstitial lung abnormalities.
It is important to consider the higher mortality rates associated with interstitial lung 
abnormalities in context; the mortality rates associated with interstitial lung abnormalities 
are less than the well documented mortality rates associated with clinically identified 
IPF.13–14 In addition, although data from the AGES-Reykjavik cohort demonstrated that 
interstitial lung abnormalities were associated with death due to respiratory failure and 
pulmonary fibrosis, respiratory failure death is more common in patients with IPF.11,27
The absolute mortality rates differed between the cohorts. This was due in part to differences 
in recruitment criteria and follow-up time. Compared to the FHS (which included a general 
population sample of adults), the higher absolute mortality rates in COPDGene and 
ECLIPSE are likely explained by a longer follow-up time (COPDGene) and the inclusion of 
greater numbers of COPD patients (COPDGene and ECLIPSE). Although the FHS and 
AGES-Reykjavik were both recruited from among community dwelling men and women, 
the higher mortality rates in the AGES-Reykjavik cohort are likely explained by the older 
age and longer follow-up times of the average participants in this cohort.
This study has a number of limitations. First, participants with interstitial lung abnormalities 
were older than those without interstitial lung abnormalities7. Further study will be required 
to determine the prognostic significance of interstitial lung abnormalities in younger age 
groups. Even among older populations, studies evaluating the longitudinal CT imaging 
progression of interstitial lung abnormalities may be required to distinguish imaging 
characteristics that could reflect a normal variant of the aging lung28 from an early stage of a 
progressive interstitial lung disease. Second, interstitial lung abnormalities were associated 
with a higher risk of death among never-smokers from two cohorts; however the large 
hazard of mortality associated with interstitial lung abnormalities in the FHS among never-
smokers was driven by a small number of deaths. Third, although an association between 
interstitial lung abnormalities and increased risk of respiratory death was identified in the 
AGES-Reykjavik study, data on the cause of death was not available from other cohorts. 
Fourth, despite the correlations presented between research participants with interstitial lung 
abnormalities and patients with IPF (as well as other forms of interstitial lung disease) this 
study cannot explain the large discrepancy between the prevalence of interstitial lung 
abnormalities (7% in general population samples,6 see Table 1) and the reported prevalence 
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of IPF (~0.002% to 0.04% of the general population)29–31 and interstitial lung disease. Of 
note, the prevalence of definite fibrosis in each cohort (~1.6–2.4%) is similar to the 
prevalence of IPF noted in an autopsy study of 510 cases from New Mexico (1.8%) even 
though IPF was suspected as a cause of death in less than a tenth of these cases.32 Fifth, 
unmeasured confounders could explain these findings. Sixth, there are differences in the 
estimates of the association of interstitial lung abnormalities on mortality in unadjusted and 
adjusted models in the FHS. Seventh, although data on inter-observer variability in 
interstitial lung abnormality scoring is presented, data on intra-observer variability in 
interstitial lung abnormality scoring was not recorded.
Follow-up studies should determine the risk factors for, and the events that lead to, death 
among persons with interstitial lung abnormalities. Given the ability to treat more advanced 
stages pulmonary fibrosis33,34 future clinical trials attempting to reduce the overall mortality 
associated with pulmonary fibrosis should consider including early stages of the disease as 
well.
Conclusions
In four separate research cohorts, interstitial lung abnormalities were associated with a 
higher risk of all-cause mortality. The clinical implications of this association require further 
investigation.
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Figure 1. 
Chest computed tomographic (CT) images of four participants, one from each cohort with 
interstitial lung abnormalities with Definite Fibrosis. Definite Fibrosis is defined as 
pulmonary parenchymal architectural distortion diagnostic of fibrotic lung disease. Each 
letter represents a different participant (A from FHS, B from AGES-Reykjavik, C from 
COPDGene, and D from ECLIPSE), in all panels images 1–3 are axial images, image 1 is at 
the level of the carina, image 2 is at the level of the right inferior pulmonary vein and image 
3 is at the base of the lungs.
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Figure 2. 
The top panel of the figure is participants included in the analysis by cohort and interstitial 
lung abnormality status. CT stands for computed tomography, FHS-MDCT2 stands for the 
Framingham Heart Study Multidetector Computed Tomography 2, and ILA stands for 
interstitial lung abnormalities. Respiratory deaths included the following: ICD9 codes 460–
519, ICD 10 codes J00-J99. Cardiovascular deaths included the following: ICD9 codes 390–
459 and ICD 10 codes I00-I99. Cancer deaths included the following: ICD9 codes 140–239 
and ICD 10 codes C00-D48. All causes of death not contained in these ICD9 and ICD10 
codes were included in “other”. *percentages were all rounded to the nearest whole number, 
at times the percentages may sum to greater than 100%
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Figure 3. 
Curves showing percent mortality, comparing participants with and without interstitial lung 
abnormalities (ILA). P-values included in each panel are those associated with the hazard 
ratios from the adjusted Cox proportional hazards model, including adjustments for age, 
gender, race, body-mass index, pack-years of smoking, current or former smoking status and 
GOLD stage of COPD (except in AGES-Reykjavik where GOLD stage was not available). 
The results are for the comparison between participants with interstitial lung abnormalities 
to participants without interstitial lung abnormalities.
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Table 1
Baseline characteristics of participants from Framingham Heart, COPDGene and ECLIPSE studies stratified 
by Interstitial Lung Abnormality (ILA) status.a
Variable
Framingham Heart Study AGES-Reykjavik COPDGene ECLIPSE
No ILA
(1370)
(52%)b
ILA
(177)
(7%)b
P-value No ILA
(3216)
(60%)b
ILA
(378)
(7%)b
P-value No ILA
(1173)
(57%)b
ILA
(156)
(8%)b
P-value No ILA
(528)
(32%)b
ILA
(157)
(9%)b
P-
value
Age – yr, mean 
(SD)
56 (11) 70 (12) <.001 76 (5) 78 (6) <.001 60 (9) 64 (9) <.001 62 (7) 64 (8) <.001
Female Sex – 
no. (%)
675 (49) 89 (50) 0.81 1910
(59)
172 (45) <.001 564 (48) 80 (51) 0.50 182 (34) 41 (26) 0.05
Race – no. white 
(%)
1370
(100)
177
(100)
N/A 3216
(100)
378
(100)
N/A 929 (79) 112 (72) 0.04 515 (98) 154 (98) 1.0
Body Mass 
Index,
mean (SD)
29 (6) 28 (5) 0.38 27 (4) 27 (5) 0.58 28 (6) 30 (7) 0.008 27 (6) 26 (5) 0.09
Pack Years 
Smoking,
median (IQR)c
11
(4, 23)
19
(9, 33)
<.001 0
(0, 16)
11
(0, 29)
<.001 40
(30, 54)
44
(30, 64)
0.06 45
(33, 62)
43
(30, 60)
0.15
Current Smokers 
– no.
(%)
73 (5) 17 (10) 0.04 374 (12) 69 (18) <.001 505 (43) 71 (46) 0.61 202 (38) 72 (46) 0.10
FEV1 (% 
predicted)d, e
mean (SD)
98 (15) 98 (17) 0.49 -- -- -- 75 (28) 78 (22) 0.10 44 (15) 47 (14) 0.02
FVC (% 
predicted)e, f
mean (SD)
101 (13) 101 (15) 0.99 -- -- -- 87 (19) 88 (17) 0.49 79 (19) 80 (20) 0.78
FEV1/FVC e 
mean (SD)
75 (7) 73 (7) <.001 -- -- -- 64 (18) 67 (14) 0.03 45 (12) 48 (11) 0.006
COPDg– no. (%) 84 (6) 19 (12) 0.01 -- -- -- 561 (41) 63 (33) 0.02 528(100)
157
(100)
N/A
GOLD Stage
Unclassified – 
no. (%)h
55 (4) 6 (4) 87 (7) 17 (11) -- --
Stage 0 – no. 
(%)
983 (76) 105 (66) 508 (43) 63 (41) -- --
Stage 1 – no. 
(%)
175 (14) 29 (18) 0.04 -- -- -- 82 (7) 21 (14) <.001 -- -- 0.01
Stage 2 – no. 
(%)
80 (6) 18 (11) 230 (20) 38 (25) 241 (46) 76 (48)
Stage 3 – no. 
(%)
4 (0.3) 1 (1) 167 (14) 11 (7) 219 (41) 74 (47)
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Variable
Framingham Heart Study AGES-Reykjavik COPDGene ECLIPSE
No ILA
(1370)
(52%)b
ILA
(177)
(7%)b
P-value No ILA
(3216)
(60%)b
ILA
(378)
(7%)b
P-value No ILA
(1173)
(57%)b
ILA
(156)
(8%)b
P-value No ILA
(528)
(32%)b
ILA
(157)
(9%)b
P-
value
Stage 4 – no. 
(%)
-- -- 99 (8) 5 (3) 68 (13) 7 (5)
TLC (Liters)e,i,
mean (SD)
5.2 (1.2) 4.5 (1.3) <.001 -- -- -- 5.8 (1.4) 5.2 (1.4) <.001 5.9 (1.5) 5.7 (1.4) 0.16
a
Baseline characteristics from FHS and COPDGene are similar to what has been previously published, now limited to those with chest CT and 
mortality data. Data are missing for participants in the following categories: FHS: current smoking status, 3 participants (0.2%); spirometry, 91 
participants (6%); total lung capacity, 93 participants (6%). COPDGene: spirometry, 1 participant (0.05%); GOLD stage, 1 participant (0.05%); and 
total lung capacity, 18 participants (1%)
b
Percentage of total population in each cohort
c
IQR is interquartile range
d
FEV1 is forced expiratory volume in 1 second.
e
In the AGES-Reykjavik cohort, approximately 80% of the spirometry was missing and TLC measurements were not available, as a result this 
information is not included in this table.
f
FVC forced vital capacity.
gCOPD refers to those with GOLD Stage 2 or higher.
hGOLD Unclassified is FEV1<80%, FEV1/FVC≥0.70
i
TLC total lung capacity. Quantitative CT total lung capacity measurements were made using Airway Inspector (www.airwayinspector.org).
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Table 2
Association between Interstitial Lung Abnormalities and Mortalitya
Framingham Heart Study AGES-Reykjavik COPDGene ECLIPSE
Median Follow Up
Time – yrs, (IQRb)
4.0
(3.3, 4.6)
8.9
(6.7, 9.9)
6.5
(6.2, 6.7)
2.9
(2.9, 2.9)
Mortality – no. (%) No ILAc
12 (1)
ILA
12 (7)
No ILA
1065 (33)
ILA
210 (56)
No ILA
133 (11)
ILA
25 (16)
No ILA
27 (5)
ILA
18 (11)
Mortality Difference
% (95% CI)d
6 (2, 10) 23 (18, 28) 5 (−1, 11) 6 (1, 11)
Hazard Ratio
(95% CI)
P-value Hazard Ratio
(95% CI)
P-value Hazard Ratio
(95% CI)
P-value Hazard Ratio
(95% CI)
P-value
Unadjusted Model 7.7
(3.7, 16.1)
<.001 1.4
(1.3, 1.6)
<.001 1.5
(0.98, 2.3)
0.08 1.5
(1.1, 2.1)
0.005
Adjusted Modele 2.7(1.1, 6.5)
0.03 1.3
(1.2, 1.4)
<.001 1.8
(1.1, 2.8)
0.01 1.4
(1.1, 2.0)
0.02
Adjusted Model +
Percentage
Emphysemaf, g
2.6
(1.03, 6.7)
0.04 -- -- 1.9
(1.2, 3.0)
0.007 1.4
(1.03, 2.0)
0.03
Adjusted Model +
Coronary
Diseaseh,g
2.2
(0.9, 5.9)
0.10 1.2
(1.1, 1.3)
<.001 1.5
(0.9, 2.0)
0.12 1.7
(1.1, 2.4)
0.008
Adjusted Model +
Cancer Historyh,g
2.6
(1.1, 6.2)
0.03 1.25
(1.2, 1.3)
<.001 1.8
(1.1, 2.8)
0.008 -- --
aAll hazard ratios are for the comparison between participants with and without interstitial lung abnormalities.
b
IQR is interquartile range
c
ILA is interstitial lung abnormalities
d95% CI is 95% Confidence Interval
eAdjusted hazard ratios include adjustments for age, gender, race, body-mass index, pack-years of smoking, current or former smoking status, 
GOLD stage of COPD (where available)
fAdjusted hazard ratios include adjustments for age, gender, race, body-mass index, pack-years of smoking, current or former smoking status, 
GOLD stage of COPD and amount of emphysema (percentage below 950 Hounsfield units).
g
Data for the variables used in addition to the baseline adjusted model can be found in eTable 4
hAdjusted hazard ratios include adjustments for age, gender, race, body-mass index, pack-years of smoking, current or former smoking status, 
GOLD stage of COPD (except in the AGES-Reykjavik where GOLD Stage was not available), history of coronary artery disease and coronary 
calcium score.
iAdjusted hazard ratios include adjustments for age, gender, race, body-mass index, pack-years of smoking, current or former smoking status, 
GOLD stage of COPD (except in the AGES-Reykjavik where GOLD Stage was not available) and history of non-dermatologic malignancy in 
Framingham and AGES-Reykjavik, in COPDGene includes a history of lung, breast, bladder, colon and prostate cancers.
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